Treat-to-target strategy for asian patients with early rheumatoid arthritis: Result of a multicenter trial in Korea

Jason Jungsik Song, Yeong Wook Song, Sang Cheol Bae, Hoon Suk Cha, Jung Yoon Choe, Sungjae Choi, Hyun Ah Kim, Jinseok Kim, Sung Soo Kim, Choong Ki Lee, Jisoo Lee, Sang Heon Lee, Shin Seok Lee, Soo Kon Lee, Sung Won Lee, Sung Hwan Park, Won Park, Seung Cheol Shim, Chang Hee Suh, Bin YooDae Hyun Yoo, Wan Hee Yoo

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) (2.6 ≤ DAS28 < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.

Original languageEnglish
Article numbere346
JournalJournal of Korean Medical Science
Volume33
Issue number52
DOIs
Publication statusPublished - 2018 Dec 24

Fingerprint

Korea
Multicenter Studies
Rheumatoid Arthritis
Joints
Antirheumatic Agents
Rheumatoid Factor
Health
Therapeutics
Prescriptions
Demography
Exercise
Antibodies

Keywords

  • Rheumatoid arthritis
  • Treat-to-target
  • Treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treat-to-target strategy for asian patients with early rheumatoid arthritis : Result of a multicenter trial in Korea. / Song, Jason Jungsik; Song, Yeong Wook; Bae, Sang Cheol; Cha, Hoon Suk; Choe, Jung Yoon; Choi, Sungjae; Kim, Hyun Ah; Kim, Jinseok; Kim, Sung Soo; Lee, Choong Ki; Lee, Jisoo; Lee, Sang Heon; Lee, Shin Seok; Lee, Soo Kon; Lee, Sung Won; Park, Sung Hwan; Park, Won; Shim, Seung Cheol; Suh, Chang Hee; Yoo, Bin; Yoo, Dae Hyun; Yoo, Wan Hee.

In: Journal of Korean Medical Science, Vol. 33, No. 52, e346, 24.12.2018.

Research output: Contribution to journalArticle

Song, JJ, Song, YW, Bae, SC, Cha, HS, Choe, JY, Choi, S, Kim, HA, Kim, J, Kim, SS, Lee, CK, Lee, J, Lee, SH, Lee, SS, Lee, SK, Lee, SW, Park, SH, Park, W, Shim, SC, Suh, CH, Yoo, B, Yoo, DH & Yoo, WH 2018, 'Treat-to-target strategy for asian patients with early rheumatoid arthritis: Result of a multicenter trial in Korea', Journal of Korean Medical Science, vol. 33, no. 52, e346. https://doi.org/10.3346/jkms.2018.33.e346
Song, Jason Jungsik ; Song, Yeong Wook ; Bae, Sang Cheol ; Cha, Hoon Suk ; Choe, Jung Yoon ; Choi, Sungjae ; Kim, Hyun Ah ; Kim, Jinseok ; Kim, Sung Soo ; Lee, Choong Ki ; Lee, Jisoo ; Lee, Sang Heon ; Lee, Shin Seok ; Lee, Soo Kon ; Lee, Sung Won ; Park, Sung Hwan ; Park, Won ; Shim, Seung Cheol ; Suh, Chang Hee ; Yoo, Bin ; Yoo, Dae Hyun ; Yoo, Wan Hee. / Treat-to-target strategy for asian patients with early rheumatoid arthritis : Result of a multicenter trial in Korea. In: Journal of Korean Medical Science. 2018 ; Vol. 33, No. 52.
@article{327e515dd3ae4cc89568546c31f295ea,
title = "Treat-to-target strategy for asian patients with early rheumatoid arthritis: Result of a multicenter trial in Korea",
abstract = "Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) (2.6 ≤ DAS28 < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5{\%} vs. 35.8{\%}; P < 0.001; remission, 43.6{\%} vs. 19.8{\%}; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0{\%} vs. 39.8{\%}; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.",
keywords = "Rheumatoid arthritis, Treat-to-target, Treatment outcome",
author = "Song, {Jason Jungsik} and Song, {Yeong Wook} and Bae, {Sang Cheol} and Cha, {Hoon Suk} and Choe, {Jung Yoon} and Sungjae Choi and Kim, {Hyun Ah} and Jinseok Kim and Kim, {Sung Soo} and Lee, {Choong Ki} and Jisoo Lee and Lee, {Sang Heon} and Lee, {Shin Seok} and Lee, {Soo Kon} and Lee, {Sung Won} and Park, {Sung Hwan} and Won Park and Shim, {Seung Cheol} and Suh, {Chang Hee} and Bin Yoo and Yoo, {Dae Hyun} and Yoo, {Wan Hee}",
year = "2018",
month = "12",
day = "24",
doi = "10.3346/jkms.2018.33.e346",
language = "English",
volume = "33",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "52",

}

TY - JOUR

T1 - Treat-to-target strategy for asian patients with early rheumatoid arthritis

T2 - Result of a multicenter trial in Korea

AU - Song, Jason Jungsik

AU - Song, Yeong Wook

AU - Bae, Sang Cheol

AU - Cha, Hoon Suk

AU - Choe, Jung Yoon

AU - Choi, Sungjae

AU - Kim, Hyun Ah

AU - Kim, Jinseok

AU - Kim, Sung Soo

AU - Lee, Choong Ki

AU - Lee, Jisoo

AU - Lee, Sang Heon

AU - Lee, Shin Seok

AU - Lee, Soo Kon

AU - Lee, Sung Won

AU - Park, Sung Hwan

AU - Park, Won

AU - Shim, Seung Cheol

AU - Suh, Chang Hee

AU - Yoo, Bin

AU - Yoo, Dae Hyun

AU - Yoo, Wan Hee

PY - 2018/12/24

Y1 - 2018/12/24

N2 - Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) (2.6 ≤ DAS28 < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.

AB - Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) (2.6 ≤ DAS28 < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.

KW - Rheumatoid arthritis

KW - Treat-to-target

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85058910437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058910437&partnerID=8YFLogxK

U2 - 10.3346/jkms.2018.33.e346

DO - 10.3346/jkms.2018.33.e346

M3 - Article

C2 - 30584418

AN - SCOPUS:85058910437

VL - 33

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 52

M1 - e346

ER -